This study is exploring if adding two anti-cancer drugs, Venetoclax and Blinatumomab, to the usual chemotherapy can better treat infants with a type of blood cancer called acute lymphoblastic leukemia (ALL). Venetoclax helps stop cancer cells by blocking a protein they need, while Blinatumomab is a special antibody that helps prevent cancer from spreading. The study will check if these drugs are safe and if they help more than standard chemotherapy alone.

• Participation Length: The study lasts up to 2 years, with various treatment phases.
• Visits Required: Patients will need multiple hospital visits for treatments and check-ups.
• Potential Risks: Adding these drugs may lead to more side effects compared to standard treatment alone.

Children under 1 year with newly diagnosed ALL, who meet certain criteria, can join. The study involves regular checks like blood tests and heart scans. After treatment, follow-up will continue for up to 3 years to monitor the long-term effects.